selected patients requiring aggressive therapy, the initial VTE treatment should be conducted with either adjusted-dose unfractionated heparin or fixed-dose low-molecular-weight heparin (LMWH). LMWHs have the potential to greatly simplify the initial treatment of VTE, making the treatment of suitable patients feasible in an outpatient setting. During anticoagulant therapy, cancer patients have a two-to four-fold higher risk of recurrent VTE and major bleeding complications when compared to non-cancer patients. The long-term administration of LMWH should be considered as an alternative to anti-vitamin K drugs in patients with advanced disease and in those with conditions limiting the use of oral anticoagulants. Prolongation of anticoagulation should be considered for as long as the malignant disorder is active. The evidence of lowered cancer mortality in patients on LMWH has stimulated renewed interest in these agents as antineoplastic drugs, and raises the distinct possibility that cancer and thrombosis share common mechanisms.
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Venous thromboembolism (VTE) is a frequent complication in cancer patients, and represents an important cause of morbidity and mortality. It has been estimated that 1 in every 7 hospitalized cancer patients who die, do so from pulmonary embolism (PE) (1) . Of these patients, 60% have localized cancer or limited metastatic disease, which would have allowed for longer survival in the absence of a fatal PE. The incidence of VTE in cancer patients has been described to be approximately 15%, with reported incidence rates ranging from 3.8 to 30.7% (2) . However, it is likely to be much higher, as VTE is often asymptomatic or minimally symptomatic, and, even when symptoms are present, they are often nonspecific or mistakenly attributed to the underlying malignancy.
According to the "Medicare Provider Analysis and Review Record", a database that records the primary discharge diagnosis and an additional four discharge diagnoses in the U.S.A, the rate of initial or recurrent thromboembolism in patients with cancer exceeds by far that recorded in those without malignancy; VTE complicates with similar frequency cancers of virtually all body systems (3).
Patients with cancer have a highly increased risk of VTE in the first few months after diagnosis and in presence of distant metastases (4) .
Moreover, this risk is further enhanced in presence of inherited thrombophilic abnormalities (4) . Most thrombotic episodes occur spontaneously, that is in the absence of triggering factors commonly accounting for thromboembolic complications in subjects without cancer (4, 5) . The most common situations that increase the thromboembolic risk in cancer patients include immobilization, surgery, chemotherapy with or without adjuvant hormone therapy, and the insertion of central venous catheters (6) 
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Since in cancer patients the occurrence of a thrombotic episode is associated with a rate of serious clinical outcomes (including bleeding and recurrent VTE) that exceeds by far that expected in patients free from malignancy, the treatment of VTE in cancer patients is resource intensive and costly (7) . Given the aging population and the inevitable rising incidence of cancer in industrialized nations, VTE in patients with cancer will become an increasingly common health issue unless more effective agents and less costly management strategies are developed in the near future (7, 8) .
TREATMENT OF ESTABLISHED VTE INITIAL TREATMENT
Therapy of VTE complications in cancer patients remains a difficult clinical challenge. Cancer patients often require invasive surgical procedures, have an increased risk of infection, and may have therapy-related platelets drop that increase their bleeding risk.
Patients with cancer who develop a VTE episode should be managed according to guidelines that are currently delivered for patients free from malignancy (9) . Especially in those cancer patients who have a poor life expectancy, preventing death from PE is the mainstay of treatment. Most patients with advanced cancer, indeed, do not survive long enough to develop late post-thrombotic sequelae or chronic pulmonary hypertension.
Intracaval filter
On average, patients with cancer present with major -often permanent -contraindications to anticoagulant treatment much more frequently than patients free from malignancy. In these patients the only
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Although a few experts question the placement of vena caval filters to prevent PE in patients with advanced malignant disease (10), I disagree with this view, as I believe that prolonging life and/or improving its quality is an invaluable goal to be achieved without hesitation even in patients in poor condition. My view is supported by recent findings from a Spanish registry. In a large number of patients with acute VTE who were managed without the insertion of a vena caval filter in spite of a recent major bleeding, the incidence of fatal bleeding and that of fatal PE in patients with cancer was 10 times as high as that observed in those without malignancy (11) .
Since it has been clearly documented that patients with vena caval filters who do not receive concomitant anticoagulation are at high risk for recurrent deep vein thrombosis (DVT) of the lower extremities (12) , only patients who are actively bleeding or who are at extremely high risk of bleeding should receive a filter without anticoagulation coverage. Once active bleeding has stopped or risk of bleeding reduced, patients with vena caval filters should receive or resume anticoagulant therapy.
Thrombolytic treatment
Those patients who present with severe hypotension or other clinical manifestations suggestive of critical PE and who do not have contraindications to thrombolysis should promptly be administered drugs that have the potential to rapidly restore the patency of obstructed pulmonary arteries (13) . Among the drugs that have been shown to achieve a rapid and substantial lysis of fresh pulmonary emboli are urokinase, streptokinase, and t-PA. I favor the last, as the administration of a loading dose of 10 mg followed by the intravenous infusion of 90 mg produces in only two hours the result that can be obtained by 12 to 24 hours of infusion of urokinase or streptokinase (14, 15) . As compared to heparin alone, the administration of t-PA relieves patients' symptoms and improves prognosis to a greater extent (16) (17) (18) . During the administration of t-PA or soon after its discontinuation heparin treatment should be implemented (16, 18) . Failure to obtain rapid clinical improvement with the infusion of thrombolytic drugs should raise the suspicion that saddle PE, arising as a consequence of tumor embolization and growth in situ, has occurred, and prompt the execution of thromboendarterectomy (19).
Recent studies have raised a renewed interest on the use of thrombolytic drugs also in those PE patients who, in spite of a stable condition, exhibit a right ventricular dysfunction as shown by echocardiography (20,21). In a recent prospective controlled study, 256 patients with submassive PE and a contemporary right ventricular dysfunction were randomly assigned to receive heparin alone or combined with t-PA (18). Treatment with heparin alone was associated with almost three times the risk of death or treatment escalation that was associated with heparin plus t-PA, and the probability of 30-day event-free survival was significantly higher in the latter group. No fatal bleeding or cerebral bleeding occurred in patients receiving heparin in combination with alteplase. The results of this study have the potential to expand the use of thrombolysis in patients with acute PE, at least in those with right ventricular dysfunction. However, given the higher hemorrhagic potential of thrombolytic drugs, particularly undesirable in cancer patients, further studies are required before thrombolysis is routinely implemented in the treatment of selected non-critical patients with PE.
As far as the role of local or systemic thrombolytic agents for acute DVT in cancer patients is concerned, available evidence is against their use except for very selected patients with massive iliofemoral thrombosis For personal use only. on October 3, 2017. by guest www.bloodjournal.org From at risk of limb gangrene, where rapid venous decompression and flow restoration may be desirable (9, 22) . In patients with contraindications to pharmacological thrombolysis, percutaneous mechanical thrombectomy can be considered (9, 22) .
Anticoagulant therapy
Except for selected patients requiring aggressive treatments, the large majority of cancer patients should be treated with either unfractionated (UFH) or low-molecular-weight heparin (LMWH) (9) .
Whenever possible, heparin should be administered as soon as there is a reasonable possibility that venous thrombosis exists.
-Unfractionated heparin
Although in clinical practice UFH has virtually been replaced by LMWHs, I think that several indications still remain for UFH, especially in cancer patients. The short half-life of intravenous UFH indeed allows for rapid reversal of anticoagulation in patients who begin to bleed or will require an invasive procedure. Therefore, in an unstable, complicated, hospitalized patient treatment with UFH is preferable. Also the presence of renal insufficiency makes it attractive to use a short-acting drug that in addition can be timely monitored and possesses a specific antidote likely to result in a favorable clinical outcome even in patients who fail to achieve a therapeutic APTT in a timely fashion (35) .
The use of heparin nomograms assures that most patients will achieve the therapeutic range for the APTT (35) . This is particularly important for cancer patients, as they have a propensity towards heparin Subcutaneous heparin treatment has been suggested as an alternative to standard heparin on the basis of the results of a metaanalysis of eight clinical trials that compared two routes of administration in the acute treatment of DVT (38) . This meta-analysis showed that subcutaneous heparin is at least as effective and safe as standard heparin, provided that a proper laboratory monitoring is performed in order to achieve a full therapeutic effect. Recently, a weight-based nomogram for the subcutaneous injection of heparin has been suggested that allows the rapid achievement of correct anticoagulation in most patients presenting with acute DVT while avoiding prolonged periods of excessive anticoagulation (39) . This modality of heparin administration, particularly desirable in those cancer patients who have difficult vein access, has been shown to be as effective and safe as LMWH for treatment of patients with acute VTE, including more than 20% of cancer patients (40) .
Of interest, the use of the APTT to predict the heparin level in patients requiring high doses of heparin has repeatedly been questioned (41, 42) . Levine et al. randomized a group of patients requiring unusually high doses of heparin to achieve a therapeutic APTT to have their heparin therapy monitored either by the level of factor Xa (targeted range, 0.35 to 0.67 U/ml) or by the APTT (targeted range, 60 to 85 seconds) (42) . The patients whose factor Xa levels were monitored required a significantly lower amount of heparin compared with the patients in the APTT group. These patients were equally protected, and experienced a lower rate of For personal use only. on October 3, 2017. by guest www.bloodjournal.org From major bleeding. The determination of the anti-Xa assay has, therefore, the potential to substitute for the APTT in those cancer patients in whom a therapeutic APTT is not reached in spite of relatively high doses of UFH, thus preventing those bleeding complications that might originate from an unnecessary increase in heparin dosage (23).
-Low-molecular-weight heparin
In recent years, LMWH derivatives of commercial heparin have been prepared that have a mean molecular weight of 4000-5000 daltons.
They present a number of potential advantages over UFH, including a longer plasma half-life, an improved subcutaneous bioavailability and less variability in response to fixed doses (23). As a result of these pharmacokinetic properties, a stable and sustained anticoagulant effect is achieved when these drugs are administered subcutaneously in doses adjusted to body weight, once or twice daily, without laboratory monitoring (9) .
These compounds have the potential to greatly simplify the initial treatment of DVT, making the treatment of suitable patients feasible in an outpatient setting (43, 44) . Treatment on home basis appears feasible and safe, which is particularly attractive for cancer patients, in whom prevention or reduction of hospital stay has the potential to improve the quality of life (32, 33, 45, 46) . According to the results of a recent worldwide survey, LMWHs are by far the most commonly used drugs for the initial treatment of VTE in cancer patients (47) .
On the basis of the results of the many comparative trials between UFH and LMWH for the initial treatment of patients with DVT that were conducted in the '90s, LMWHs appear to be at least as effective and safe as UFH both in patients with and in those without cancer (48, 49) . It should be noted, however, that in these clinical trials cancer patients represented only 10-15% of the total population, as the majority of them were excluded because of their poor performance status. Of interest, the use of LMWH was associated with a significantly lower mortality, which was essentially dependent on the reduction of cancer-related mortality (48, 49) .
To test the hypothesis that LMWH treatment can be extended to cover the entire spectrum of patients presenting with acute VTE (thus including also patients with non-critical PE), two multicentre clinical trials In analogy with the use of UFH, patients undergoing LMWH treatment require close monitoring of platelet count, as the risk of heparininduced thrombocytopenia in medical patients treated with LMWH may not be different from that observed during UFH administration (53).
-Beyond heparins
New categories of drugs are emerging that have the potential to rapidly change the therapeutic scenario both in patients with and in those 
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response that is more predictable because there is no binding to plasma proteins, and a lack of potential to produce immune thrombocytopenia.
Among these preparations, ximelagatran (an oral prodrug that is converted to melagatran and does not require laboratory monitoring)
show promise for treatment of VTE. Ximelagatran can be employed as the sole treatment in patients with VTE, which is especially desirable in patients with cancer.
The double-blind, phase III THRIVE treatment study randomized 2491 patients with acute DVT with or without clinically symptomatic PE, including approximately 15% with cancer, to receive either oral ximelagatran (36 mg twice daily) alone for 6 months or conventional doses of enoxaparin followed by warfarin (57) . In this trial, ximelagatran was found to be as effective and safe as conventional treatment. It should be noted, however, that in approximately 9% of patients receiving ximelagatran an increase of liver enzymes (more than three times the upper limit of the normal value) was observed, which was transient in the large majority of patients. In summary, cancer patients have a three-to four-fold higher risk of recurrent VTE during anticoagulant therapy than cancer-free patients, very likely as a consequence of the release of cancer procoagulants that are not inhibited by conventional anticoagulation. Among findings that have been described in association with an increased risk of recurrent VTE in cancer patients are development of new metastases, multiple episodes of neutropenia, and previous VTE (61) . This risk correlates with the extent of cancer (60) . Accordingly, more aggressive initial or long-term treatment has the potential to reduce the risk of recurrent thrombosis.
However, a complicating factor in improving anticoagulant therapy in
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cancer patients is the occurrence of excess bleeding in combination with excess recurrent VTE complications. Although some improvements can be expected from optimizing laboratory monitoring of anticoagulant therapy, most bleeding and thrombotic complications occur in patients with anticoagulant parameters within the therapeutic range. Therefore, a change in anticoagulant intensity is a case of Hobson's choice where it is likely to achieve less thrombotic complications for the price of more bleeding or less bleeding for more thrombotic complications. Possibilities for improvement using the current paradigms of anticoagulation seem, therefore, limited and new treatment strategies should be developed.
According to the results of recent randomized clinical trials and prospective cohort studies, LMWHs in full doses for the first month followed by a dose ranging from 50 to 75% of the initial regimen has the potential to provide a more effective antithrombotic regimen in cancer patients with venous thrombosis than the conventional treatment, and is not associated with an increased hemorrhagic risk (62, 63) , even in patients with disseminated cancer such as those with liver or brain metastases (64) . In addition, LMWHs provide an anticoagulation that is easier to administer, more convenient and flexible, and not influenced by nutrition problems or liver impairment (6, 8) . Thus, the long-term administration of LMWH should now be considered the treatment of choice in patients with metastatic disease and in those with conditions limiting the use of oral anticoagulants (9) . However, as the cost of the long-term prophylaxis of recurrent VTE with LMWH exceeds by far that of oral anticoagulants (65) , and increases the risk of osteoporosis (66) , I
think that the use of LMWHs for this indication should not be generalized.
Since the rate of recurrent VTE and bleeding complications exceeds that of non-cancer patients only in those with advanced disease (36), I still recommend warfarin prophylaxis in patients with less advanced disease. 
According to the results of a recent worldwide survey, vitamin K antagonists are still the most commonly used drugs for long-term prevention of recurrent VTE in cancer patients (47) .
As new categories of drugs are emerging that have the potential to replace conventional treatment for the secondary prevention of VTE (67), major improvements are soon expected for long-term treatment of cancer patients with venous thrombosis.
The optimal duration
According to the results of recent prospective cohort and populationbased studies (68) (69) (70) , after discontinuation of antithrombotic treatment cancer patients with venous thrombosis present a risk for recurrences that is almost twice as high as that observed in patients free from malignancies. Among the factors associated with an increased risk of recurrent VTE after anticoagulation withdrawal in cancer patients are residual vein thrombosis, as determined by compression ultrasound on the day of drug suspension, and abnormal D-dimer values, measured on the day of drug suspension and one month later (71) . In view of the persistently high risk of recurrent thrombotic events, prolongation of anticoagulation should be considered for as long as the malignant disorder is active provided that it is not contraindicated. For most patients, this translates into life-long anticoagulation. Anyway, also in candidates to long-term anticoagulation, this decision should be frequently reassessed during patients' follow-up.
TREATMENT OF RECURRENT VTE
The anticoagulation strategy in the treatment of patients with recurrent venous thromboembolism during oral anticoagulation is not rigidly standardized (6, 8) . A patient who develops recurrent VTE while the For patients with a high risk of pulmonary embolism, or who are hemodynamically unstable, an inferior vena caval filter can be inserted in addition to any one of the above options.
IMPACT OF ANTITHROMBOTIC DRUGS ON CANCER EVOLUTION AND DEVELOPMENT
Anticoagulant treatment of cancer patients, particularly those with lung cancer, has been reported to improve survival (73) . Since then, studies conducted in animal tumor models have demonstrated that both UFH and LMWH interfere with various processes involved in tumor growth and metastasis (74) . These processes might include fibrin formation, binding (75) (76) (77) (78) . Two of these studies showed a favorable impact of the tested heparin on patients' survival, this result being particularly evident in those with better prognosis (75, 78) . In the other two studies, a post-hoc analysis showed a better survival in subgroups of patients with less advanced disease (76, 77) . These results are encouraging, but further studies on wider samples of patients are needed before LMWH can be implemented in the routine treatment of patients with cancer.
Of interest, in a recent trial addressing the value of different durations of warfarin for prevention of recurrent thromboembolism in patients with the first episode of VTE, the development of late malignancies was recorded much more frequently in patients allocated to six weeks than in those allocated to six months of anticoagulation (79) .
These results raise the distinct possibility that cancer and thrombosis 
